Collplant Biotechnologies Ltd
collplant.comWhat Do They Do?
Develops and sells plant-produced human collagen, bioinks and regenerative products for medical aesthetics, tissue repair and organ research to business partners, collaborators and research customers.
20-F for FY2025, filed Mar 26, 2026In February 2021, we entered into the AbbVie Development Agreement with Allergan, an AbbVie company, pursuant to which dermal and soft…View ↗
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products…View ↗
We sell our rhCollagen and bioinks directly to our business partners, collaborators and selective customers. We anticipate that any…View ↗
In December 2020, we entered into a product manufacturing and supply agreement with STEMCELL Technologies, or STEMCELL, a biotechnology…View ↗
How Do They Make Money?
AbbVie pays milestone amounts when CollPlant reaches development targets under its dermal and soft-tissue filler agreement. The company also sells rhCollagen and collagen-based goods; payment terms generally call for advance payment, though some customers have up to 60 days.
20-F for FY2025, filed Mar 26, 2026In February 2021, we entered into the AbbVie Development Agreement with Allergan, an AbbVie company, pursuant to which dermal and soft…View ↗
Payment terms and conditions vary by contract type, although terms generally include requirement to pay the consideration in advance, but…View ↗
The Company’s products include the rhCollagen and rhCollagen-based products and include the bioink products for the development of 3D…View ↗
-
20-F for FY2025, filed Mar 26, 2026
FY2025 revenue by product or service ↗
$2.4M
-
20-F for FY2025, filed Mar 26, 2026
$2.4M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Revenues from licensing agreement
Licensed
20-F for FY2025, filed Mar 26, 2026 |
84% |
Revenues from licensing agreement, FY2025
$2M Sources
|
Licensed |
|
Revenues from the Sales of Goods
Sold outright
20-F for FY2025, filed Mar 26, 2026 |
16%
FY2022: 100%
|
Revenues from the Sales of Goods, FY2025
$371K Sources
|
Sold outright |
Who Are Their Customers?
CollPlant sells rhCollagen and bioinks directly to business partners, collaborators and selected customers; VergenixSTR reaches buyers through distributors in Benelux and Poland. Partners are expected to market products developed with CollPlant.
20-F for FY2025, filed Mar 26, 2026
Do Revenues Turn Into Profits?
No. It lost $11.5M in FY2025.
20-F for FY2025, filed Mar 26, 2026
−$11.5MView ↗
20-F for FY2025, filed Mar 26, 2026
−$11.5MView ↗
20-F for FY2025, filed Mar 26, 2026
−$9.4MView ↗
How Are They Changing?
Shrinking. Revenue fell 85% in 4 years, from $15.6M in FY2021 to $2.4M in FY2025, about 38% a year.
Broader STEMCELL applications
Earlier, STEMCELL distributed kits for the regenerative medicine research market; the latest report says the expanded agreement covers clinical development and commercial-scale manufacturing as well.
20-F for FY2022, filed Mar 29, 2023 20-F for FY2025, filed Mar 26, 2026Previously, in December 2020, we entered into a product manufacturing and supply agreement with STEMCELL. As part of the agreement, we are…View ↗
In December 2020, we entered into a product manufacturing and supply agreement with STEMCELL Technologies, or STEMCELL, a biotechnology…View ↗
Who Do They Compete With?
Competes with Galderma, Merz Aesthetics, Sinclair, AbbVie, Allergan, Establishment Labs Holdings, Mentor Worldwide, BICO, Allevi, Humabiologics, Zimmer Biomet, Harvest Technologies, and Arteriocyte Medical Systems
20-F for FY2025, filed Mar 26, 2026The main competitors to our dermal/soft tissue fillers that are in development with AbbVie include Galderma, Merz Aesthetics, Sinclair and…View ↗
Loading...
